文献速递血液透析通路

两期手术与单期动静脉造瘘相比无优势:一项多中心全国数据分析

Two-Stage Offers No Advantages over Single-Stage Arteriovenous Creation: An Analysis of Multicenter National Data.
PubMed 文献 · Ann Vasc Surg · 2023-03-31

基于血管质量倡议(VQI)2011至2021年22910例头静脉-贵要静脉动静脉瘘患者,比较单期与计划两期手术的结局。两期组透析使用率更高但首次使用延迟、并发症更多;随访成熟率与通畅率无差异。作者建议在静脉直径合适时行单期手术。

要点

  • 两期组使用指数瘘管透析比例31.5% vs 单期组22.2%(P<0.0001)。
  • 当前透析患者单期组至使用天数103.9天 vs 两期组141.0天(P<0.0001)。
  • 两期组术后并发症1.6% vs 单期组1.1%(P=0.026)。

核心结论

  • 使用贵要静脉建立透析通路时,单期与两期手术在成熟率和1年通畅率方面无差异。
  • 两期手术显著延迟瘘管首次使用时间并增加术后并发症。
  • 作者建议当静脉直径合适时行单期手术,以减少多次手术、并发症并加快成熟。

研究设计与样本

  • 研究为基于血管质量倡议(VQI)2011至2021年数据的多中心分析。
  • 共纳入22910例接受贵要静脉动静脉瘘(AVF)建立的患者,其中7077例(30.9%)行计划两期手术,15833例(69.1%)行单期手术。
  • 单期组平均随访345天,两期组平均随访420天。
  • 采用逻辑回归模型评估分期手术与主要结局的关联,并用样条模型探索术前静脉直径的切点。

主要发现

  • 两期组使用指数瘘管透析的患者比例高于单期组(31.5% vs 22.2%,P<0.0001)。
  • 当前透析患者中,单期组至瘘管使用天数为103.9天,两期组为141.0天(P<0.0001)。
  • 随访时成熟率单期组19.3%,两期组17.4%(P=0.354),无显著差异。
  • 30天死亡率与通畅率无差异:通畅率单期组89.8%,两期组89.1%(P=0.383)。
  • 术后并发症两期组1.6%,单期组1.1%(P=0.026)。

关键数值与推荐

  • 主要结局:使用指数瘘管透析比例两期组31.5% vs 单期组22.2%(P<0.0001)。
  • 至瘘管使用天数:单期组103.9天 vs 两期组141.0天(P<0.0001)。
  • 成熟率:单期组19.3% vs 两期组17.4%(P=0.354)。
  • 通畅率:单期组89.8% vs 两期组89.1%(P=0.383)。
  • 术后并发症:两期组1.6% vs 单期组1.1%(P=0.026)。

临床怎么用

  • 作者建议当静脉直径合适时行单期手术,以减少多次手术、并发症并加快成熟。
  • 术前静脉直径3 mm或以下可能是考虑两期手术的切点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Traditionally, arteriovenous fistulas (AVF) involving the basilic vein (BV) have been created in 1 or 2 stages to allow time for the vein to enlarge before superficialization for potential better fistula maturation. Previous single institution studies and meta-analyses have found conflicting outcomes between single-stage and 2-stage procedures. Our study aims to use a large national database to assess the difference in outcomes between single-stage and 2-stage procedures for dialysis access. METHODS: We studied all patients undergoing BV AVF creation in the Vascular Quality Initiative (VQI) from 2011 to 2021. Patients were split into single-stage or a planned 2-stage procedure for dialysis access. Primary outcomes included dialysis use with index fistula, maturity rate, and number of days from surgery to fistula use. Secondary outcomes included patency (defined by physical exam or imaging on follow-up), 30-day mortality, and postoperative complications (bleeding, steal syndrome, thrombosis, or neuropathy). Logistic regression models were used to assess the association between staged dialysis access procedures and primary outcomes of interest. RESULTS: The cohort consisted of 22,910 individuals of which 7,077 (30.9%) had a 2-staged dialysis access procedure and 15,833 (69.1%) had a single-staged procedure. Average follow-up was 345 days in the single stage and 420 days for 2-stage. Baseline characteristics were significantly different between the 2 groups in terms of medical comorbidities. Primary outcomes were significant for more patients in the 2-stage group undergoing dialysis with the index fistula compared to single stage (31.5% vs. 22.2%, P < 0.0001), significant decrease in days to use in current dialysis patients (103.9 days single stage versus 141.0 days 2-stage, P < 0.0001), and no difference in maturity at follow-up (19.3% single-stage and 17.4% 2-stage, P = 0.354). Secondary outcomes revealed no difference in 30-day mortality or patency (89.8% single-stage and 89.1% 2-stage, P = 0.383), but a significant difference in postoperative complications with a 2-stage procedure compared to 1-stage (1.6% vs. 1.1%, P = 0.026). Finally, a spline model was used to determine that a preoperative vein of 3 mm or less could be a cutoff in which a 2-stage procedure might be beneficial. CONCLUSIONS: This study demonstrates that when dialysis access fistulas are created using the BV, there is no difference in maturity rate or 1-year patency when assessing single-stage versus 2-stage procedures. However, 2-stage procedures significantly delay the time of first use of the fistula and increase postoperative complications. Therefore, we suggest performing single stage procedures when the vein is of appropriate diameter to minimize multiple procedures, complications and expedite time to maturity.

来源:Ann Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Patel RJ, Willie-Permor D, Zarrintan S, et al. Two-Stage Offers No Advantages over Single-Stage Arteriovenous Creation: An Analysis of Multicenter National Data. Ann Vasc Surg. 2023. PMID: 37004922. doi:10.1016/j.avsg.2023.03.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。